TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cellectis SA ( (CLLS) ) has shared an announcement.
On November 19, 2025, Cellectis published an article in Nature Communications highlighting a breakthrough in non-viral gene editing. The company introduced circular single-stranded DNA (CssDNA) as an efficient non-viral DNA donor template for gene insertion in hematopoietic stem and progenitor cells (HSPCs). This innovation significantly enhances the potential of non-viral gene therapy by achieving higher knock-in efficiency and applicability to multiple cell types, marking a pivotal advance in the development of next-generation cell and gene therapies.
The most recent analyst rating on (CLLS) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is primarily influenced by its financial performance, which is challenged by persistent losses and cash flow issues. Technical analysis shows a positive trend, but valuation remains a concern due to negative earnings. The earnings call provided positive sentiment with advancements in clinical trials and strategic partnerships, although legal uncertainties remain.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis is a clinical-stage biotechnology company that utilizes a pioneering gene-editing platform to develop life-saving cell and gene therapies. The company focuses on an allogeneic approach for CAR T immunotherapies in oncology, offering off-the-shelf gene-edited CAR T-cells for cancer treatment, and also develops gene therapies for other therapeutic indications. Cellectis controls the entire cell and gene therapy value chain with its in-house manufacturing capabilities.
Average Trading Volume: 129,436
Technical Sentiment Signal: Buy
Current Market Cap: $308.4M
Learn more about CLLS stock on TipRanks’ Stock Analysis page.